Nadda Releases Indian Pharmacopoeia 2026
10th edition boosts global acceptance, adds 121 new drug standards and introduces blood component monographs
- Indian Pharmacopoeia now recognised in 19 Global South countries
- 121 new monographs added; total standards rise to 3,340
- India jumps from 123rd to 8th globally in WHO pharmacovigilance contributions
- Blood component monographs introduced for the first time
GG News Bureau
New Delhi, 2nd Jan: Union Minister for Health and Family Welfare and Chemicals and Fertilizers, J. P. Nadda, on Friday released the Indian Pharmacopoeia 2026 (IP 2026), the 10th edition of India’s official book of drug standards, at the Dr. Ambedkar International Centre in New Delhi.
Addressing the gathering, Nadda said the Indian Pharmacopoeia is a cornerstone of India’s pharmaceutical regulatory framework and reflects the country’s scientific advancement, global best practices and leadership in medicine manufacturing. He noted that IP 2026 has incorporated 121 new monographs, taking the total to 3,340, with expanded coverage of anti-tubercular, anti-diabetic, anti-cancer medicines and iron supplements.
Highlighting India’s rising global stature, the Minister said the Pharmacopoeia is now recognised in 19 countries of the Global South. He also pointed out that India has climbed from 123rd position during 2009–2014 to 8th globally in 2025 in contributions to the World Health Organization’s pharmacovigilance database.
For the first time, 20 blood component monographs for transfusion medicine have been included in IP 2026 in line with Drugs and Cosmetics (Second Amendment) Rules, 2020. Shri Nadda said this move would further strengthen patient safety, regulatory vigilance and quality assurance.
Union Health Secretary Punya Salila Srivastava said the new edition reinforces India’s commitment to science-based, globally harmonised pharmaceutical standards, enhancing the country’s role in the global medicine supply chain.
